Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective C  

$2,302,240.00
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.

Download 2010 Question 4: Long-term Objective C projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD Scahill, Lawrence Yale University
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McCracken, James University of California, Los Angeles
2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD King, Bryan Seattle Children's Hospital
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Indiana University-Purdue University Indianapolis
Targeted pharmacologic interventions for autism McDougle, Christopher Indiana University-Purdue University Indianapolis
1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McDougle, Christopher Indiana University-Purdue University Indianapolis
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders McDougle, Christopher Indiana University